American Sales Company, LLC v. Pfizer, Inc. et al

  1. April 19, 2018

    Pfizer Gets Final Nod On $94M Celebrex Antitrust Settlement

    A Virginia federal judge signed off Wednesday on Pfizer's $94 million settlement, including nearly $31 million in legal fees, with drug buyers who said the pharmaceutical giant extended its monopoly over the anti-inflammatory Celebrex by illegally blocking generic competition.

  2. January 09, 2018

    Hagens Berman, Others Want $31M In Pfizer Celebrex Deal

    Hagens Berman Sobol Shapiro LLP, Berger & Montague PC and a handful of other firms on Monday asked a Virginia federal court to grant them about $31 million in fees after reaching a $94 million settlement with Pfizer Inc. over allegations that the company blocked competition for its anti-inflammatory drug Celebrex.

  3. November 27, 2017

    Pfizer Reaches $94M Settlement Over Celebrex Claims

    Pfizer and a class of direct purchasers who allege the drugmaker used fraudulent patents to delay generic competition for its anti-inflammatory drug Celebrex have told a Virginia federal court that they have reached a $94 million settlement agreement.

  4. June 28, 2017

    Pfizer, Direct Buyers Duel For Quick Wins In Celebrex Suit

    Pfizer and a proposed class of direct purchasers who allege the drugmaker used fraudulent patents to delay generic-drug competition for its Celebrex painkiller filed dueling motions for summary judgment in Virginia federal court Tuesday about whether Pfizer was wrongly reissued an invalid patent.

  5. May 25, 2017

    Pfizer Says Expert Testimony In Celebrex Suit Unreliable

    Pfizer asked a Virginia federal judge Wednesday to exclude expert testimony supporting the certification of a class of direct purchasers who allege the drugmaker used fraudulent patents to delay generic-drug competition for its Celebrex painkiller, saying the testimony is not reliable.

  6. April 06, 2017

    Celebrex Buyers Seek Class Cert. In Pfizer Antitrust Suit

    Purchasers of popular painkiller Celebrex on Wednesday asked a Virginia federal court to certify as a class action its suit against Pfizer accusing the drug giant of using fraudulent patents to delay generic-drug competition and maintain supracompetitive prices for the drug.

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!